Showing results (511-520 of 529) with videos related to
Sort By:
Pageof 53
Journal of Toxicology|August 23, 2021
Toxicity of Nanoparticles in Biomedical Application: NanotoxicologyChukwuebuka Egbuna, Vijaykumar K Parmar, Jaison Jeevanandam, et al.Blood|September 12, 2022
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agentsAdam D Cohen, María-Victoria Mateos, Yael C Cohen, et al.The International Journal of Behavioral Nutrition and Physical Activity|November 29, 2024
Associations of perceived neighbourhood and home environments with sedentary behaviour among adolescents in 14 countries: the IPEN adolescent cross sectional observational studyRanjit Mohan Anjana, Harish Ranjani, Ester Cerin, et al.Blood Cancer Journal|February 25, 2022
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studiesAdam D Cohen, Samir Parekh, Bianca D Santomasso, et al.Current Topics in Medicinal Chemistry|May 10, 2021
Bioactive Compounds Effective Against Type 2 Diabetes Mellitus: A Systematic ReviewChukwuebuka Egbuna, Chinaza G Awuchi, Garima Kushwaha, et al.Asian Pacific Journal of Cancer Prevention : APJCP|September 22, 2012
Prognostically significant fusion oncogenes in Pakistani patients with adult acute lymphoblastic leukemia and their association with disease biology and outcomeNoreen Sabir, Zafar Iqbal, Aamer Aleem, et al.Environmental Science and Pollution Research International|January 6, 2017
Optimizing the phosphorus use in cotton by using CSM-CROPGRO-cotton model for semi-arid climate of Vehari-Punjab, PakistanAsad Amin, Wajid Nasim, Muhammad Mubeen, et al.Clinical Lymphoma, Myeloma & Leukemia|May 20, 2026
Non-ICANS Neurologic Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Ciltacabtagene Autoleucel: Clinical Presentation and Management in CARTITUDE StudiesPaula Rodríguez-Otero, Jaime Gállego Pérez-Larraya, Yi Lin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2025
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple MyelomaSundar Jagannath, Thomas G Martin, Yi Lin, et al.Lancet (London, England)|June 27, 2021
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label studyJesus G Berdeja, Deepu Madduri, Saad Z Usmani, et al.Pageof 53